AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

od Zielinski, Christoph C, Pinto, Carmine
izdano v ESMO Open (2016)

ESMO Open—Cancer Horizons and the future of oncology

od Zielinski, Christoph C
izdano v ESMO Open (2016)

CSCO joins ESMO Open—Cancer Horizons

od Zielinski, Christoph C, Wu, Yi-Long
izdano v ESMO Open (2016)

ESMO Open: news in breast cancer 2019

od Lambertini, Matteo
izdano v ESMO Open (2020)

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

od Ohe, Yuichiro, Zielinski, Christoph
izdano v ESMO Open (2017)

ESMO Open special series on new emerging targets in cancer immunotherapy

od Lambertini, Matteo
izdano v ESMO Open (2020)

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

od Morgan, Gilberto, Preusser, Matthias, Zielinski, Christoph
izdano v ESMO Open (2020)

One year of ESMO Open: Cancer Horizons—where are we going from here?

od Zielinski, Christoph
izdano v ESMO Open (2017)

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

od Preusser, Matthias
izdano v ESMO Open (2019)

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

od Burke, Patrick W, Hoelzer, Dieter, Park, Jae H, Schmiegelow, Kjeld, Douer, Dan
izdano v ESMO Open (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

od Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
izdano v ESMO Open (2020)

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

od Awada, Ahmad, Gligorov, Joseph, Jerusalem, Guy, Preusser, Matthias, Singer, Christian, Zielinski, Christoph
izdano v ESMO Open (2019)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

od Lambertini, Matteo, Preusser, Matthias, Zielinski, Christoph C
izdano v ESMO Open (2019)

Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

od Lamarca, A., Foster, L., Satyadas, T., Siriwardena, A., Valle, J.W.
izdano v ESMO Open (2021)

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

od Peleg Hasson, S., Brezis, M.R., Shachar, E., Shachar, S.S., Wolf, I., Sonnenblick, A.
izdano v ESMO Open (2021)

A lei geral de proteção de dados e o open finance

od Holz, Carlos Eduardo
Izdano 2022

Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

od Shi, L., Xu, C., Ma, Y., Ou, Q., Wu, X., Lu, S., Shao, Y., Guo, R., Kong, J.
izdano v ESMO Open (2021)

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue...

od Lee, R.J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., Aung, T., Banfill, K., Baxter, M., Boyce, H., Brearton, G., Copson, E., Dickens, E., Eastlake, L., Gomes, F., Hague, C., Harrison, M., Horsley, L., Huddar, P., Hudson, Z., Khan, S., Khan, U.T., Maynard, A., McKenzie, H., Palmer, D., Robinson, T., Rowe, M., Thomas, A., Tweedy, J., Sheehan, R., Stockdale, A., Weaver, J., Williams, S., Wilson, C., Zhou, C., Dive, C., Cooksley, T., Palmieri, C., Freitas, A., Armstrong, A.C.
izdano v ESMO Open (2021)

Simulação de grandes escalas de uma chama turbulenta e radiante de metano usando o OpenFOAM

od Almeida, Yuri Paixão de
Izdano 2013-08

The atomic age opens /

Izdano 1945